Hans Wigzell - Swedish Orphan Independent Director
| BIOVF Stock | USD 22.87 2.13 8.52% |
Director
Dr. Hans Wigzell M.D. Ph.D. is Independent Member of the Board of Swedish Orphan Biovitrum AB and has held this position since 2005. He also serves as Chairman of the Company Scientific Committee. Mr. Wigzell is a former Vice Chancellor of Karolinska Institutet. He was also Board member of NeoDynamics AB PROBI AB and Diamyd Medical AB. He holds membership at the Royal Swedish Academy of Sciences and the Royal Swedish Academy of Engineering Sciences. Apart from this he is Chairman of Rhenman Partners Asset Management AB and Cadila Pharmaceuticals Svenska AB and serves as Board Member at Karolinska Development AB RaySearch Laboratories AB Valneva SE Sarepta Therapeutics Inc. and AB Wigzellproduktion. Mr. Wigzell is Professor emeritus of Immunology. He holds M.D. and D.Sc. degrees. since 2005.
| Age | 77 |
| Tenure | 19 years |
| Professional Marks | Ph.D |
| Phone | 46 86 97 20 00 |
| Web | https://www.sobi.com |
Hans Wigzell Latest Insider Activity
Tracking and analyzing the buying and selling activities of Hans Wigzell against Swedish Orphan pink sheet is an integral part of due diligence when investing in Swedish Orphan. Hans Wigzell insider activity provides valuable insight into whether Swedish Orphan is net buyers or sellers over its current business cycle. Note, Swedish Orphan insiders must abide by specific rules, including filing SEC forms every time they buy or sell Swedish Orphan'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Hans Wigzell over a year ago Acquisition by Hans Wigzell of 1523 shares of Sarepta Therapeutics subject to Rule 16b-3 |
Swedish Orphan Management Efficiency
The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1061 %, meaning that it generated $0.1061 on every $100 dollars invested by stockholders. Swedish Orphan's management efficiency ratios could be used to measure how well Swedish Orphan manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Frank Cousins | Provident Bancorp | 55 | |
| Kristen Hege | Mersana Therapeutics | 54 | |
| David Herndon | Home Federal Bancorp | 79 | |
| Timothy Wilhite | Home Federal Bancorp | 48 | |
| John Bosen | Provident Bancorp | 49 | |
| Walter Colquitt | Home Federal Bancorp | 72 | |
| Russell Howard | Immutep Ltd ADR | 64 | |
| Frederic MD | Immutep Ltd ADR | 69 | |
| Laurie Knapp | Provident Bancorp | 56 | |
| Rafal Kozlowski | Formula Systems 1985 | 41 | |
| Jay Gould | Provident Bancorp | N/A | |
| Andrew Hack | Mersana Therapeutics | 43 | |
| Lisa DeStefano | Provident Bancorp | N/A | |
| Lawrence Alleva | Mersana Therapeutics | 67 | |
| Arthur Sullivan | Provident Bancorp | N/A | |
| Richard Peeke | Provident Bancorp | 69 | |
| Woodus Humphrey | Home Federal Bancorp | 77 | |
| Willard Dere | Mersana Therapeutics | 64 | |
| Marek Panek | Formula Systems 1985 | 45 | |
| Elizabeth Donnelly | Marker Therapeutics | N/A | |
| Eliyahu Zamir | Formula Systems 1985 | 46 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 |
Swedish Orphan Biovitrum Leadership Team
Elected by the shareholders, the Swedish Orphan's board of directors comprises two types of representatives: Swedish Orphan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Swedish. The board's role is to monitor Swedish Orphan's management team and ensure that shareholders' interests are well served. Swedish Orphan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Swedish Orphan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lennart Johansson, Director | ||
| Thomas Larsen, Head Relations | ||
| Rami Levin, Head of North America | ||
| Dennis Pedersen, Senior Vice President Human Resources | ||
| Armin MD, Head Affairs | ||
| Alan Raffensperger, COO and Sr. VP | ||
| Fredrik Berg, Head of Legal and Intellectual Property, Risk- Safety and Environment Management and General Counsel | ||
| BoGunnar Rosenbrand, Director, Employee Representative | ||
| Adine Axen, Independent Director | ||
| Hakan Bjorklund, Independent Chairman of the Board | ||
| Cecilia Forberg, Vice President Head of Project and Portfolio Management | ||
| Stephen James, Vice President Head of Drug Design and Development | ||
| Bo Hansen, Chairman of the Board | ||
| Armin Reininger, Senior Vice President Head of Global Medical and Scientific Affairs | ||
| Henrik Stenqvist, Chief Officer | ||
| David Allsop, Director | ||
| Torbjorn Hallberg, General Counsel and Head of Legal Affairs | ||
| Christine Wesstrom, Head Operations | ||
| Theresa Heggie, Independent Director | ||
| Torbjrn Hallberg, G HR | ||
| Hans Wigzell, Independent Director | ||
| Annette Clancy, Independent Director | ||
| Paula Treutiger, Head of Communications & Investor Relations | ||
| Trista Morrison, Vice President - Communications for North America | ||
| Daniel Rankin, Head Devel | ||
| Kirsti Gjellan, Senior Vice President Manufacturing Operations | ||
| Jorgen Winroth, Head of Investor Relations and VP | ||
| Milan Zdravkovic, Senior Vice President Head of Research & Development | ||
| Norbert Oppitz, Head of Specialty Care | ||
| Hans Schikan, Independent Director | ||
| Konstantina Karampela, Director Operations | ||
| Helena Saxon, Director | ||
| Anne Schuermans, Head of Technical Operations | ||
| Anders Edvell, Head of Marketing and Sales | ||
| Sofiane Fahmy, Head of Southern and Western Europe & North Africa | ||
| Pablo Mora, Head Access | ||
| Philip Wood, Head of Haemophilia | ||
| Geoffrey McDonough, CEO | ||
| Lars Dreioee, Senior Vice President Chief Quality & Compliance Officer | ||
| Fredrik Wetterlundh, Head of Human Resources | ||
| Amy Pott, Head of North America | ||
| Birgitte Volck, Senior Vice President Chief Medical Officer | ||
| MatsOlof Wallin, CFO, Senior Vice President | ||
| Stefan Fraenkel, Vice President Head of Corporate Development | ||
| Hege Hellstrom, Head of EMENAR | ||
| Catarina Larsson, Director, Employee Representative | ||
| Anders MD, Head Officer | ||
| Elisabeth Svanberg, Director | ||
| Christian Dreger, Head of Northern Europe, Middle East & Russia | ||
| Wills HughesWilson, Senior Vice President and Chief Patient Access Officer | ||
| Guido Oelkers, President CEO | ||
| Pia Axelsson, Director, Employee Representative | ||
| Jeffrey Jonas, Independent Director | ||
| Matthew Gantz, Director | ||
| Pia Axelson, Director, Employee Representative |
Swedish Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Swedish Orphan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Current Valuation | 7.05 B | |||
| Shares Outstanding | 295.99 M | |||
| Shares Owned By Insiders | 4.00 % | |||
| Shares Owned By Institutions | 70.55 % | |||
| Price To Earning | 20.33 X | |||
| Price To Book | 2.58 X | |||
| Price To Sales | 3.68 X |
Pair Trading with Swedish Orphan
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Swedish Orphan position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Swedish Orphan will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Swedish Orphan could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Swedish Orphan when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Swedish Orphan - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Swedish Orphan Biovitrum to buy it.
The correlation of Swedish Orphan is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Swedish Orphan moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Swedish Orphan Biovitrum moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Swedish Orphan can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Swedish Orphan Biovitrum. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Swedish Pink Sheet analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |